INTRODUCTION
============

The prevalence of major depressive disorder (MDD) worldwide is estimated to be 5% \[[@b1-pi-2019-0236]\], and, in addition to being a disabling disorder, it also has a serious impact on health by increasing suicide risk and mortality risk from cardiovascular and cerebrovascular diseases \[[@b2-pi-2019-0236]\]. MDD generally assumes a chronic course and causes functional impairment due to frequent relapse after remission. Although effective treatment methods are available, there are some limitations to these treatments. Some patients do not experience alleviation of symptoms despite several trials of adequate psychopharmacological and psychological therapy. Insufficiently treated depression results in the burden of residual symptoms and inflated risk for subsequent recurrence or overt treatment-resistance depression (TRD) \[[@b3-pi-2019-0236]\]. In addition, currently approved antidepressants generally take several weeks to produce an effect. Therefore, the need for a more effective and rapid-acting antidepressant is evident \[[@b4-pi-2019-0236],[@b5-pi-2019-0236]\].

In particular, these problems arise in pharmacotherapy because most of the antidepressants currently available target the monoamine system. First, although an overwhelming majority of antidepressants target the monoamine system, a relatively high proportion of patients have TRD despite pharmacotherapy \[[@b3-pi-2019-0236]\]. In the large-scale, Sequenced Treatment Alternatives to Relieve Depression Study conducted in the United States, as high as 46% of the patients did not respond to firstand second-line treatment with monoamine antidepressants \[[@b6-pi-2019-0236]\], and the final remission rate was only 13% to 14% in patients who did not achieve remission when treated with the initial two antidepressants \[[@b3-pi-2019-0236]\]. The second problem is the delayed onset of the therapeutic effect of current antidepressants. In animal studies, serotonin and norepinephrine reuptake inhibitors induced an initial increase in neurotransmitters in mice within few hours or days of administration; however, improvement in key depressive symptoms was observed few weeks after the administration \[[@b7-pi-2019-0236]\]. Patients who received antidepressant treatment also exhibited actual improvement in symptoms after a given period after treatment \[[@b8-pi-2019-0236]-[@b10-pi-2019-0236]\]. Monoamine antidepressants may take time to neurochemically desensitize through the administration of an antidepressant followed by a 5-HT1A autoreceptor that normally inhibits serotonin release at the nerve terminal. In another hypothesis, monoamine antidepressants can promote neuroplasticity but this function be delayed because such plasticity is achieved through complex cascades \[[@b11-pi-2019-0236]\]. Lastly, most of the current monoamine-modulating antidepressants carry side-effects of variable degrees, sometimes involving the therapeutic joint effects both in the acute- and long-term settings \[[@b12-pi-2019-0236],[@b13-pi-2019-0236]\]. Such limitations to the use of monoamines serve as a stimulus for the development of novel antidepressants with different mechanisms of action.

The development of antidepressants with a novel target has seen a focus on the glutamatergic system \[[@b14-pi-2019-0236]\]. The glutamate system is associated with the pathophysiology of mood disorders in various aspects. Autopsy studies have reported abnormal levels of glutamate in the cerebrospinal fluid, plasma, serum, and brain tissue of individuals with a mood disorder \[[@b15-pi-2019-0236]-[@b18-pi-2019-0236]\]. Moreover, magnetic resonance spectroscopy imaging studies found abnormal levels and abnormal ratio of glutamate and gamma-aminobutyric acid (GABA) in some brain regions associated with mood \[[@b19-pi-2019-0236],[@b20-pi-2019-0236]\]. Glial cells play an important role in the regulation of glutamate signaling and can partially affect depression \[[@b21-pi-2019-0236]\]. Glial cells are extensively involved in glutamate metabolism and degradation, and loss of glial cells has been observed in the frontal cortex of patients with mood disorder. In addition, it has been discovered that chronic stress may damage astrocytes in the cerebral cortex and lead to development of depression \[[@b22-pi-2019-0236]\]. Reduced glial cell function due to chronic stress causes reduction in extracellular glutamate degradation and increased activation of NR2B-containing glutamatergic N-methyl-D-aspartate (NMDA) receptors, eventually leading to synaptic loss and activation of the apoptotic pathway.

Ketamine is an NMDA receptor antagonist prescribed as an anesthetic but also used off-label to treat chronic pain. After the study demonstrating that a subanesthetic dose of ketamine, when administered intravenously over 40 minutes, may have a rapid onset of antidepressant effect in patients with MDD, ketamine has been a focus of attention as a novel antidepressant with a novel target \[[@b23-pi-2019-0236]\]. Since then, evidence has been accumulating with many trials in patients with MDD. The rapid-acting antidepressant actions of ketamine have several complex molecular and cellular mechanisms, including NMDA receptor-mediated signaling, inhibition of extrasynaptic NMDA receptors, and ketamine metabolite actions, as well as the blockade of NMDA receptors in the synapse. In addition, intranasal ketamine for TRD has recently been approved by the FDA to ensure ease of administration and continuous use to sustain antidepressant treatment \[[@b24-pi-2019-0236]\].

In this study, we reviewed the mechanism of action of ketamine as an antidepressant, its efficacy in treating MDD, and the safety and misuse potential of ketamine prescription, with a special focus on recent randomized control trials (RCTs).

METHODS
=======

While it was our intent to systematically cover the existing literature about ketamine for treating MDD, we did not follow a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@b25-pi-2019-0236]\] approach for a systematic review in the present report considering the anticipated publication bias in RCTs, especially concerning Phase-IV trials for non-intravenous ketamine for TRD. We rather opted for a narrative synthesis of the evidence promoting RCT appraisal whenever available. In contrast, in the absence of an RCT, we preferred to critically appraise the evidence by utilizing manual search, cross-reference augmentation, and consulting with the experts (as needed) in order to promote critical evaluation of the drug.

THE MECHANISM OF ACTION OF KETAMINE AS AN ANTIDEPRESSANT
========================================================

NMDA receptor blockade paradigm
-------------------------------

### Neurochemical antidepressant mechanism by blockade of NMDA receptor

NMDA receptors are glutamatergic and heterotetrameric ligand- gated ion channel receptors that are activated by concurrent binding of L-glutamate and glycine or D-serine to the GluN2 and GluN1 subunits or via flow of calcium ions when a depolarization repels the Mg2+ block from the ion channel pore in a voltage-dependent manner. In a forced swim test in mice, it was demonstrated that a non-competitive NMDA receptor antagonist and a competitive NMDA receptor antagonist have an antidepressant effect of reducing the duration of immobility in these mice \[[@b26-pi-2019-0236]\]. In the same experiment, long-term administration of antidepressants reduced the binding of a radioactive ligand to the NMDA receptors, which was believed to be an adaptive change of the receptor. Therefore, the researchers suggested that rapid-acting antidepressant actions were caused by direct blockade of NMDA receptors.

Ketamine blocks excitatory glutamate signaling and increases the overall activity of the prefrontal cortex \[[@b27-pi-2019-0236]\] by preferentially inhibiting NMDA receptors expressed in GABA neurons \[[@b28-pi-2019-0236],[@b29-pi-2019-0236]\]. This mechanism is supported by a preclinical study, which found that a non-competitive NMDA receptor antagonist, dizocilpine, inhibited the firing of GABA interneurons but increased the firing of pyramidal neurons. Ketamine has a high affinity for the GluN2D subunit of the GluN2D-NMDA receptors that are highly expressed in the inhibitory interneurons of the forebrain \[[@b30-pi-2019-0236]\]. It is predicted that inhibition of NMDA receptors in GABAergic interneurons induces a general decrease in inhibition, which will then disinhibit pyramidal neurons and strengthen excitatory glutamate signaling in the medial prefrontal cortex \[[@b28-pi-2019-0236]\]. When a subanesthetic dose of ketamine is administered to mice, the extracellular glutamate concentration and glutamate cycling in the prefrontal cortex are increased \[[@b28-pi-2019-0236],[@b31-pi-2019-0236]\].

Ketamine may induce antidepressant actions through direct inhibition of extrasynaptic NMDA receptors. The presence of extrasynaptic NMDA receptors has been demonstrated through immunohistochemical and electrophysiological studies \[[@b32-pi-2019-0236]\]. GluN2B-containing extrasynaptic NMDA receptors located in dendrites near glial cells are not activated by transient synaptic glutamate release but are chronically activated by low levels of glutamate in the extracellular space \[[@b33-pi-2019-0236],[@b34-pi-2019-0236]\]. This tonic glutamate level is regulated by the glutamate transporter, EAAT2, which is expressed in glial cells. Ketamine inhibits glutamateinduced tonic actions through specific inhibition of extrasynaptic GluN2B-NMDA receptors, and this is presumed to induce excitation of pyramidal neurons \[[@b35-pi-2019-0236]\]. Activation of extrasyna ptic GluN2B-selective NMDA receptors occurs through the mTOR signaling pathway associated with inhibition of protein synthesis for homeostatic synaptic scaling \[[@b35-pi-2019-0236]-[@b37-pi-2019-0236]\], and, as such, blockade of the above receptors may induce antidepressant actions via disinhibition of protein synthesis and an mTOR-dependent mechanism. Although selective antagonism of GluN2B-containing NMDA receptors produces antidepressant actions, it is not as rapid-acting as the antidepressant effects of ketamine through other mechanisms. GluN2B-NMDA receptor antagonists, traxoprodil and MK-0657, elicited significant antidepressant actions approximately five days after their infusion \[[@b38-pi-2019-0236],[@b39-pi-2019-0236]\].

The lateral habenula is an epithalamic structure that plays a mediating role between the monoaminergic systems and the forebrain and midbrain \[[@b40-pi-2019-0236]\]. Activation of the lateral habenula neurons is associated with depression-like phenotypes in depressed animals and humans. In mice, depression and fatigue were associated with increased activity burst in the lateral habenula neurons \[[@b41-pi-2019-0236]\]. Direct application of ketamine to the lateral habenula neurons decreased the abnormally high levels of NMDA receptor-dependent firing bursts and induced immediate antidepressant effects \[[@b41-pi-2019-0236]\]. Further studies are needed to investigate whether other types of rapid-acting antidepressants share the same mechanism of action, whether these effects converge with other antidepressant actions of ketamine, and if the same results can be obtained in humans.

### The mechanism of enhancing synaptic plasticity by blockade of NMDA receptor

The mechanism underlying the action of rapid-acting antidepressants comes from rapid changes in synaptic functions and neural plasticity. Ketamine increases the mTORC1 signaling through Akt and ERK activation and increases the number and function of synapses in the prefrontal cortex \[[@b35-pi-2019-0236],[@b42-pi-2019-0236],[@b43-pi-2019-0236]\]. This leads to increased synthesis of proteins required for the formation and maturation of synapses, which may be blocked by pre-infusion with a selective mTORC1 inhibitor rapamycin \[[@b35-pi-2019-0236],[@b42-pi-2019-0236],[@b44-pi-2019-0236]\]. The rapid activation of mTORC1 and dendritic mRNA translation of synaptic proteins by ketamine triggers continuous synapse formation and behavioral changes.

Ketamine-mediated mTORC1 activation, synapse formation, and antidepressant actions are determined by glutamate signaling and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activation. Animal and clinical studies found that blockade of NMDA receptors on GABAergic interneurons increased glutamate signaling \[[@b28-pi-2019-0236],[@b29-pi-2019-0236],[@b45-pi-2019-0236]\]. In addition, activation of the AMPA receptor induced the release of BDNF in neurons and mTORC1 signaling through Akt and ERK signaling \[[@b46-pi-2019-0236],[@b47-pi-2019-0236]\]. In contrast to ketamine's activity-dependent BDNF release, monoamine antidepressants do not induce the release of BDNF but increase BDNF expression through complex intracellular signaling cascades \[[@b48-pi-2019-0236]\]. This process is relatively slower than the antidepressant action of ketamine \[[@b11-pi-2019-0236]\].

The rapid induction of mTORC1 signaling and synaptogenesis recovers the synaptic loss between neurons in patients with depression and restores the ability to adequately control emotions in the prefrontal lobe and amygdala. This has been demonstrated by a chronic stress-depression rat model exposed to stress for several weeks \[[@b49-pi-2019-0236]\]. The rats in this study exhibited prefrontal neuron atrophy and anhedonia, which are characteristic of depression; however, a single dose of ketamine rapidly improved the aforementioned structural deficit and behavioral problems. This has also been demonstrated with brain imaging studies in animals and in clinical studies showing that ketamine increased the connectivity of the prefrontal lobe with the limbic system in species with depression \[[@b50-pi-2019-0236],[@b51-pi-2019-0236]\].

Independent synaptic vesicle glutamate release via independent fusion of synaptic vesicles at presynaptic terminals induces miniature excitatory postsynaptic currents (mEPSCs), which regulate synaptic strength and protein synthesis \[[@b52-pi-2019-0236]-[@b54-pi-2019-0236]\]. mEPSCs inhibit protein synthesis while blocking NMDA receptor-mediated neurotransmission, and the resulting selective depletion of vesicles led to synaptic strengthening in the hippocampus \[[@b54-pi-2019-0236]\]. Ketamine blocked resting NMDA receptor-mediated neurotransmission, eliciting disinhibition of protein synthesis leading to the induction of synaptic strengthening in the CA1 regions of the hippocampus and improving depression \[[@b54-pi-2019-0236],[@b55-pi-2019-0236]\]. The inhibition of NMDA receptor-mediated neurotransmission by ketamine occurs in the presence of physiological concentrations of Mg2+ and leads to a rapid-acting antidepressant action \[[@b56-pi-2019-0236]\]. This is different from memantine, which is reduced in NMDA receptor antagonism-mediated mEPSCs at the physiological level of Mg2+ and lacks a rapid-acting antidepressant action \[[@b56-pi-2019-0236]\].

NMDA receptor blockade-independent paradigm
-------------------------------------------

### Evidence of NMDA receptor inhibition-independent mechanism of action

After the discovery of the ability of ketamine to produce rapid-acting and long-lasting antidepressant actions, clinical trials were conducted to investigate the antidepressant potential of other NMDA receptor antagonists with similar NMDA inhibition as ketamine. However, clinical trials showed that these alternative NMDA receptor antagonists lack the rapidacting and long-lasting antidepressant actions of ketamine \[[@b57-pi-2019-0236]\]. In particular, memantine, a prescription drug for the treatment of moderate to severe dementia related to Alzheimer's disease, repeatedly failed to produce antidepressant actions in patients with MDD \[[@b58-pi-2019-0236],[@b59-pi-2019-0236]\]. In addition, a non-selective NMDA receptor antagonist, lanicemine, did not reproduce the longlasting antidepressant effect of ketamine in MDD patients \[[@b60-pi-2019-0236]\], and in the follow-up clinical trial, no significant difference was found between adjunctive lanicemine treatment and placebo treatment \[[@b61-pi-2019-0236]\]. This suggests an antidepressant mechanism of ketamine that is independent of NMDA receptor inhibition.

### Antidepressant action of metabolites of ketamine

(2S,6S;2R,6R)-hydroxynorketamine (HNK) is a key metabolite of ketamine found in the plasma and brain in humans \[[@b62-pi-2019-0236]\]. (2S,6S;2R,6R)-HNK has been considered inactive since it does not affect anesthetic action. An animal study found evidence that the metabolism of ketamine to (2S,6S;2R,6R)-HNK is needed for its antidepressant actions \[[@b63-pi-2019-0236]\]. Chemical alteration of ketamine by deuteration at the C6 position did not change the binding affinity of ketamine for NMDA receptors but sharply reduced its metabolism to (2S,6S;2R,6R)-HNK. This alteration blocked the antidepressant actions of ketamine in mice and demonstrated that (2S,6S;2R,6R)-HNK is required for ketamine antidepressant responses. However, in a recent contradictory study, mice were pretreated with cytochrome p450 inhibitors and did not show (2R,6R)-HNK after administration of (R)-ketamine induced an antidepressant action, indicating that (2R,6R)-HNK is not essential for ketamine's antidepressant action \[[@b64-pi-2019-0236]\]. Therefore, it is still difficult to conclude that ketamine metabolites have antidepressant action, and human data on it are also needed.

EFFICACY OF KETAMINE IN MDD
===========================

Evidence in support of intravenous injection of ketamine for MDD
----------------------------------------------------------------

In 2000, Berman et al. \[[@b23-pi-2019-0236]\] investigated ketamine as a potential antidepressant for the first time. Using a small number of subjects (n=7), they found that mood symptoms rapidly improved within four hours in response to ketamine (0.5 mg/kg infusion over 40 minutes) infusion, whereas no response was found with placebo (normal saline) infusion. Ketamine infusion reduced the Hamilton Depression Rating Scale score, a measure of depression severity, by an average of 13 points. This result was reproduced in a subsequent crossover study \[[@b65-pi-2019-0236]\]. Patients who had previously failed at least two antidepressant clinical treatments were treated with ketamine or placebo and then crossed over one week later. Rapid antidepressant effects were observed within 2 hours post-infusion in patients treated with ketamine when compared with placebo-treated individuals.

In a placebo-controlled study, it is difficult for a non-active placebo such as normal saline to produce a dissociative effect that peaks at 15 to 30 minutes after the start of infusion. In order to enhance the effect of blinding, some researchers used midazolam, a short-acting benzodiazepine, in an active control group; 0.045 mg/kg midazolam produces perceptual and cognitive changes with infusion times similar to that of ketamine and may be intravenously administered. However, it must be taken into consideration that benzodiazepines may also have antidepressant effects \[[@b66-pi-2019-0236]\]. Murrough et al. \[[@b67-pi-2019-0236]\] were the first to conduct a parallel, double-blind, randomized study with ketamine and midazolam for treating TRD. Patients with TRD not undergoing pharmacotherapy were randomly assigned to receive a ketamine or midazolam infusion (2:1 ratio). In the ketamine group, 30 out of 47 patients showed a response within 24 hours of infusion (50% or greater reduction in symptoms), whereas 7 out of 25 patients in the midazolam group showed a response. The antidepressant effects of ketamine are superior to those of midazolam; however, the effect size for the antidepressant effect of ketamine somewhat decreases when compared to that in studies that used saline solution as a placebo.

Two studies of the same design found antidepressant effects of ketamine on bipolar depression in patients with treatmentresistant bipolar depression \[[@b68-pi-2019-0236],[@b69-pi-2019-0236]\]. The subjects were maintained on lithium or valproate prior to the study protocol. Using a crossover design with a one-week wash-out period, it was found that ketamine produces a rapid antidepressant effect in bipolar depression. However, the effect started to disappear within one week of infusion in most of the patients.

Sos et al. \[[@b70-pi-2019-0236]\] randomly assigned 30 hospitalized patients to first receive ketamine or a placebo, and then they were crossed over after one week. In this protocol, the ketamine dose was different. Subjects received 0.27 mg/kg over 10 minutes, followed by an additional 0.27 mg/kg for 20 minutes (0.54 mg/kg administered over 30 minutes). Ketamine produced a stronger and superior effect than placebo, as 10 out of 27 patients had a response after ketamine infusion, while only 1 out of 19 patients had a response after placebo infusion.

Hu et al. \[[@b71-pi-2019-0236]\] investigated the efficacy of single-dose ketamine augmentation of standard antidepressants. In this parallel study, 30 patients with severe major depressive disorder were randomly assigned to ketamine \[0.5 mg/kg intravenous (IV) infusion over 40 minutes\] or a placebo group. All patients were started on escitalopram on the same day of ketamine infusion. At week 4 of treatment, the response and remission rates of the ketamine group were greater when compared to those of the placebo group. The time until the response of the ketamine group was shorter than that of the placebo group.

Based on the fact that patients with chronic pain sometimes receive prolonged ketamine infusion \[[@b72-pi-2019-0236]\], Lenze et al. \[[@b73-pi-2019-0236]\] applied a similar protocol in their study of depression. Twenty participants were randomly assigned to two groups that received a continuous infusion of 0.6 mg/kg/h ketamine for 96 hours and a standard ketamine infusion (0.5 mg/kg over 40 minutes). In this protocol, both groups received clonidine in order to prevent dissociative and psychotomimetic effects and minimize the increase in blood pressure. Bipolar symptoms were measured using the Brief Psychiatric Rating Scale, and although the score peaked on day 3 in the 96-ketamine infusion group, the changes of these symptoms were similar to those obtained with the standard protocol. Rapid and sustained improvement in depressive symptoms was found in both protocol groups.

A meta-analysis of the aforementioned seven double-blind RCTs employing an IV infusion and one RCT employing intranasal (IN) ketamine in the treatment of major depressive episodes in patients with bipolar disorder and MDD showed that a single administration of ketamine may have rapid antidepressant effects \[[@b74-pi-2019-0236]\].

All the previous studies, to date, were RCTs with relatively small number of subjects. A large-scale RCT comprising a large number of subjects is being conducted and the results are currently being reported ([Table 1](#t1-pi-2019-0236){ref-type="table"}). In order to establish evidence on the optimal ketamine dose, an RCT compared 0.1 (n=18), 0.2 (n=20), 0.5 (n=22), and 1.0 mg (n=20) ketamine with an active placebo (midazolam 0.45 mg/kg, n=19) in TRD. This comparison showed that, although the effect of a low dose (0.1 and 0.2 mg/kg) ketamine was ambiguous, a ketamine dose of 0.5 mg/kg or greater was clearly more efficacious than the active placebo \[[@b75-pi-2019-0236]\]. Other studies in which repeated infusions following a single dose infusion were employed and the analyses of the efficacy of this infusion regimen at different times are discussed in the following section.

A single dose IV ketamine administration produced consistent antidepressant effects only for a maximum of seven days; therefore, there is a need to investigate whether repeated ketamine infusion produces a better response rate and better maintenance of antidepressant effects. In the first open-label study that investigated the effect of six IV ketamine infusions over two weeks, 70.8% of patients with TRD showed a response, and the median relapse time was 18 days. Treatment results were strongly predicted by the response at four hours after the first infusion.

In contrast, a study, in which 28 participants with unipolar and bipolar TRD received IV ketamine infusion three or six times a week over three weeks, showed that 29% of the patients responded to the ketamine treatment \[[@b76-pi-2019-0236]\]. In this study, 11% of the patients showed a response within six hours after a single dose infusion, and in all responders, a response was seen before the third infusion. Further, following the last infusion, the treatment effect lasted for 25 to 168 days.

However, in an RCT of 26 patients with severe TRD and chronic suicidal ideation who received six IV ketamine augmentation doses or placebo for over three weeks, the ketamine infusion group did not show a higher treatment effect when compared to the placebo infusion group. The authors suggested that a standard 0.5 mg/kg dose or administration period may be insufficient for patients with severe TRD and chronic suicidal ideation \[[@b77-pi-2019-0236]\].

According to the first multicenter RCT (n=67) in which a twice-weekly or thrice-weekly IV ketamine (0.5 mg/kg administered over 40 minutes for four weeks) group was compared with a twice-weekly or thrice-weekly IV placebo group, both ketamine doses were similarly effective in reducing depressive symptoms in contrast to the placebo \[[@b78-pi-2019-0236]\]. In this study, all responders also responded before the third administration. The adverse effect profiles were similar between the twiceweekly and thrice-weekly groups.

A recent repeated ketamine infusion study evaluated the cumulative and sustained therapeutic effects of repeated ketamine infusion after confirming the efficacy of a single dose infusion. Phillips et al. \[[@b79-pi-2019-0236]\] found that, in 46 patients with TRD, a single IV infusion of ketamine produced a greater reduction in depressive symptoms when compared to that with the active control, midazolam. The patients then received six ketamine infusions administered thrice weekly over two weeks, and 59% of the patients had a 50% or greater decrease in their Montgomery-Åsberg Depression Rating Scale score (MADRS). These patients then received a maintenance treatment once a week for four weeks, and their MADRS score was maintained without relapse.

Evidence in support of intranasal injection of ketamine for MDD
---------------------------------------------------------------

Ketamine has been administered intranasally as an analgesic, and this form of administration is known to be less invasive and well-tolerated than IV infusion \[[@b80-pi-2019-0236],[@b81-pi-2019-0236]\]. Intranasal ketamine has been shown to be effective within minutes, which has been hypothetically suggested due to blockage of the NMDA receptor circuits that generate the emotional representations of pain \[[@b82-pi-2019-0236]\]. Lapidus et al. \[[@b83-pi-2019-0236]\] firstly investigated whether IN ketamine administration produces an antidepressant effect in patients with MDD. Eighteen patients with TRD were randomized to receive 50 mg of IN racemic ketamine or placebo before the end of a one-week drug-free period. At 24 hours following administration, 8 out of 18 patients showed a response to ketamine treatment and only 1 out of 18 showed a response to placebo treatment.

In a recently published study, participants were randomized into a placebo and s-ketamine 28, 56, or 84 mg twice weekly groups at a 3:1:1:1 ratio, and patients in the placebo group who had moderate to severe symptoms were randomly assigned again to the three ketamine groups \[[@b84-pi-2019-0236]\]. The participants then received infusion twice weekly for two weeks, followed by an open-label treatment with administration once weekly for three weeks followed by a maintenance infusion once every two weeks for up to 10 weeks. In this study, all the ketamine groups demonstrated superior antidepressant effects than the placebo group. In addition, it was concluded that the antidepressant effect was sustained even with reduced dosing frequency.

A placebo-controlled study designed to investigate the maintenance effect of ketamine treatment was recently reported. In this RCT, patients with MDD (n=121) who achieved remission or stable response (50% or greater reduction in MADRS score for two weeks or longer) after IN s-ketamine treatment, received additional administration of 56 or 84 mg esketamine as an adjunctive therapy plus an oral antidepressant during the maintenance phase. Relapse was significantly delayed in the ketamine group \[[@b85-pi-2019-0236]\].

In a recent study, IN ketamine flexible doses (28, 56, or 84 mg) twice weekly for 4 weeks with oral antidepressants significantly reduced the depressive symptoms in TRD patients \[[@b86-pi-2019-0236]\]. In contrast, an abstract of an unpublished study using the same design showed that IN ketamine plus oral antidepressant did not significantly reduce the depressive symptoms in TRD patients \>65 years of age in all the study regions except in the United States \[[@b87-pi-2019-0236]\].

THE RAPID-ACTING ANTI-SUICIDAL EFFECT OF KETAMINE
=================================================

Suicidal ideation is the most serious symptom of depression and is one of the leading causes of death \[[@b88-pi-2019-0236]\]. Suicidal ideation has been suggested as a symptom caused by cognitive dysfunction, especially associated with dysregulation of glutaminergic neurotransmission in the prefrontal cortex in patients with MDD with suicidal ideation. The antidepressant effects of ketamine through the glutamate pathway has been reported to exert anti-suicidal effect by preclinical studies \[[@b89-pi-2019-0236]\]. Although most pharmacological studies on depression exclude individuals with imminent risk of suicide, several ketamine studies have included patients with a moderate level of suicidal ideation. In many case series and open-label studies, ketamine infusion consistently reduced suicidal ideation \[[@b90-pi-2019-0236]\]. A review of an RCT on the effects of ketamine on suicidality showed that a single infusion of ketamine reduced suicidal ideation in patients with TRD \[[@b91-pi-2019-0236]\]. A study involving suicidal psychiatric inpatients with various mood and anxiety spectrum disorders (n=24) showed that, when compared with midazolam, IV ketamine produced a significant reduction in suicidal ideation at post-infusion day 2, although the significance was lost at day 7 \[[@b92-pi-2019-0236]\]. In an RCT of 80 MDD patients with suicidal ideation, suicidal ideation was significantly reduced in the single adjunctive subanesthetic IV ketamine infusion group (n=40) when compared with the midazolam control group (n=40) and the observed decrease in suicidal ideation was maintained following infusion \[[@b93-pi-2019-0236]\]. In an RCT to determine the effect of IN esketamine on depressive symptoms and suicidal thoughts in MDD patients at risk for suicide, repeated infusion of 84 mg of IN esketamine (twice weekly through day 25, once weekly through day 52, and once every other week through day 81) significantly decreased the MADRS total score and MADRS suicidal ideation item scores when compared with IN-placebo infusion \[[@b94-pi-2019-0236]\]. In a recent RCT, ketamine administration in MDD patients reduced the functional connectivity of the left dorsolateral prefrontal cortex and the left dorsal anterior cingulate cortex \[[@b95-pi-2019-0236]\]. This seems to correlate with the antidepressant and anti-suicidal effects of ketamine infusion. Rapid improvement of suicidal ideation suggests that ketamine may be administered first in a clinical setting when urgent treatment is needed, as in patients with suicidal ideation or behavior.

SAFETY AND ABUSE ISSUES
=======================

It has been demonstrated that healthy volunteers experience psychotomimetic symptoms, perceptual impairment, dissociative symptoms, or reduced cognitive function during ketamine infusion using the standard protocol (0.5 mg/kg over 40 minutes or longer intravenously) \[[@b96-pi-2019-0236],[@b97-pi-2019-0236]\]. These side effects were resolved within approximately 40 to 80 minutes of infusion completion. Patients with a mood disorder have shown, with repeated dosing, some resistance to the acute dissociative and psychotic symptoms induced by ketamine. Moreover, subjects with TRD who received low dose IV ketamine showed improvement in cognitive function \[[@b98-pi-2019-0236]\].

A meta-analysis of depression reported that a single use of ketamine for the treatment of depression can cause adverse symptoms including dizziness, blurred vision, headache, nausea, vomiting, and dry mouth as other mild side effects, but these were generally not serious and resolved after dose administration \[[@b99-pi-2019-0236]\]. It has also been proposed that, although the side effect of blood pressure elevation during and shortly after a 40-minute ketamine infusion is transient, careful monitoring is required for patients with a history of cardiovascular disease as transient blood pressure elevations may be problematic in such patients \[[@b100-pi-2019-0236]\]. A recent systemic review reported that it is still difficult to conclude that repeated dosing of ketamine has a cumulative effect and long-term risk because of insufficient data \[[@b101-pi-2019-0236]\].

Lamotrigine, and other glutamate release-inhibiting drugs may reduce hyper-glutamatergic consequences presented as perceptual abnormalities \[[@b102-pi-2019-0236]\]. Thus, glutamatergic inhibition of lamotrigine could prevent hyperglutamatergic activation due to ketamine abuse, with potential benefit identified in some case reports \[[@b103-pi-2019-0236]\]. This property of lamotrigine may cause downregulation of ketamine's antidepressant action.

The interaction of ketamine and opioid receptors, including mu, delta, and kappa, have been considered to have an antinociceptive role in acute and chronic pain. Interestingly, in human studies, pretreatment with naltrexone, an opioid receptor antagonist, decreased the antidepressant action of ketamine but did not alter its dissociative effects \[[@b104-pi-2019-0236]\]. This suggests that the opioid system may play an important role in the antidepressant action of ketamine, but may not be involved in the development of adverse effects (dissociative symptoms).

Whether repeated use of ketamine can result in prolonged cognitive and perceptual changes or psychosis-like symptoms is an important issue. This is especially important because a method for maintaining the antidepressant effects of ketamine without repeated ketamine exposure is unclear. The most useful evidence for the long-term effects of ketamine comes from a study involving ketamine abusers. Although it is evident that reduced cognitive function, thought disorder, or neuropsychiatric abnormality, including depression, may arise from ketamine abuse, this is dose-dependent and limited to frequent users who use ketamine almost every day \[[@b105-pi-2019-0236]\].

Because ketamine has been used as a recreational drug, there is a potential for patients to abuse its use or to develop a use disorder \[[@b106-pi-2019-0236]\]. Ketamine abuse is a common global problem, and, although the prevalence of its abuse in Korea has not been studied, 1.7% of adolescents in the United States abuse it one or more times a year \[[@b107-pi-2019-0236]\]. Ketamine abuse is also common in the Asian regions of Hong Kong and Taiwan, with a prevalence of 1.1% to 1.8% \[[@b108-pi-2019-0236]\]. However, many aspects of ketamine abuse are not yet well known, including risk factors that increase ketamine abuse. A long-term study is needed to investigate whether ketamine use in patients with depression leads to its abuse.

PREDICTOR OF RESPONSE TO KETAMINE
=================================

Several clinical studies have demonstrated the efficacy of ketamine infusion in resolving symptoms in patients with MDD. It is not yet well-known which patients will have favorable outcomes after ketamine treatment. An evaluation of ketamine responders vs. non-responders after a single infusion showed no difference in patients with different demographic and clinical characteristics \[[@b98-pi-2019-0236]\]. A study by Murrough et al. \[[@b109-pi-2019-0236]\] found that, in a neuropsychology test, slower processing speed at baseline was a predictor of larger improvements in depression at 24 hours following ketamine treatment. This finding is in contrast with that of a previous study that predicted that a slow processing speed is associated with poor antidepressant response \[[@b110-pi-2019-0236]\]. Monteggia et al. \[[@b111-pi-2019-0236]\] suggested that high body mass index, family history of alcohol use disorder, and anxiety were clinical predictors of ketamine treatment. An earlier study found that patients with anxious depression responded better to ketamine treatment \[[@b112-pi-2019-0236]\]. However, a recent study found no difference in the response to ketamine infusion between patients with anxious and non-anxious depression \[[@b113-pi-2019-0236]\]. More research on the predictors of ketamine treatment response in patients with MDD is still needed.

CONCLUSIONS
===========

Mounting evidence supports the acute therapeutic efficacy of ketamine for MDD; however, several issues need clarification, if ketamine is to be used as an antidepressant. Clinical trials are being conducted to optimize the efficacy of ketamine, indicating the lack of standard guidelines, outside of the research environment. Recently, large-scale RCTs have outlined the administration protocol for the use of ketamine as an antidepressant. IN and IV ketamine administration are effective for MDD in subanesthetic doses, with an ascending dose-response relationship. However, low doses (below 0.5 mg/kg) of IV ketamine cannot ensure an antidepressant effect. In terms of treatment frequency, two to three repeated ketamine administrations per week may be required to maintain antidepressant efficacy. Moreover, weekly maintenance doses could be used for maintaining remission or a significant response. The minimal adverse effects of ketamine at subanesthetic doses observed during the trials were encouraging in terms of its safety.

Little is known about the safety of long-term exposure to subanesthetic doses of ketamine when prescribed as an antidepressant; it is presumed that some data will become available from a small observational study on ketamine abusers, which is currently underway. Considering that an increasing number of medical institutions have been using ketamine, off-label, for the treatment of psychological disorders \[[@b114-pi-2019-0236]\], studies on evidence-based treatment methods and a better understanding of the long-term risks of ketamine are indispensable.

We emphasize that IN ketamine will be in widespread use in the future because IN ketamine is less invasive and easier to use than IV ketamine. Recently, a large-scale clinical trial of the effects of IN ketamine on MDD successfully ended, with the efficacy and safety of IN ketamine considerably clarified. Subsequently, IN ketamine (trade name: Spravato) was approved by the FDA as an adjunct to oral antidepressants for TRD \[[@b24-pi-2019-0236],[@b115-pi-2019-0236]\]. Clearly, IN formulations of ketamine are restricted for use only under medical supervision at medical institutions.

In conclusion, important studies support the efficacy of ketamine as rapid-acting pharmacotherapy for patients with MDD. Clinicians should remember that information related to the optimum dose and the long-term effects of ketamine treatment are still being updated. As more evidence becomes available in the future, ketamine is expected to have important clinical applications in the rapid resolution of serious depressive symptoms, including suicidal ideation, and as an effective treatment for TRD.
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###### 

RCTs published since 2018 (N＞40 for each RCT)

  Study                                                                                       Main purpose                                                                                                                           Target diagnosis                                                                    Design                                                                                                                                                                    Route of administration   Sample size   Primary outcome                     Main result
  ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ------------- ----------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Singh et al. \[[@b78-pi-2019-0236]\]                                                        To assess dosefrequency in IV ketamine therapy                                                                                         TRD                                                                                 Double-blind, randomized, placebo-controlled trial                                                                                                                        IV                        67            MADRS                               Twice-weekly and thrice-weekly administrations of ketamine similarly maintained antidepressant efficacy over 15 days
  IV ketamine vs. IV placebo, either two or three times weekly, for up to 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Fava et al. \[[@b75-pi-2019-0236]\]                                                         To assess doseranging in IV ketamine therapy                                                                                           TRD                                                                                 Double-blind, randomized, placebo-controlled trial                                                                                                                        IV                        99            HAMD-6, MADRS                       Confirm the efficacy of the 0.5 mg/kg and 1.0 mg/kg doses of IV ketamine
  IV dose of ketamine 0.1 mg/kg, 0.2 mg/kg, 0.5 mg/kg, 1.0 mg/kg, and midazolam 0.045 mg/kg   No clinically meaningful efficacy of lower doses of IV ketamine                                                                                                                                                                                                                                                                                                                                                                                                                  
  Daly et al. \[[@b84-pi-2019-0236]\]                                                         To assess doseresponse of in esketamine                                                                                                TRD                                                                                 Double-blind, randomized, placebo-controlled trial                                                                                                                        IN                        60            MADRS                               AD effect of IN ketamine was rapid in onset and was dose related
  IN dose of ketamine 28 mg, 56 mg, 84 mg, and placebo                                        Response appeared to persist for more than 2 months with a lower dosing frequency                                                                                                                                                                                                                                                                                                                                                                                                
  Grunebaum et al. \[[@b93-pi-2019-0236]\]                                                    To assess rapid relieve of suicidal ideation by ketamine                                                                               MDD with suicidal ideation                                                          Double-blind, randomized, placebo-controlled trial                                                                                                                        IV                        80            Scale for Suicidal Ideation score   Adjunctive ketamine demonstrated rapid and greater reduction of suicidal ideation in depressed patients compared with midazolam
  AD+adjunctive IV ketamine on suicidal ideation in MDD (vs. AD+adjunctive IV placebo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Phillips et al. \[[@b79-pi-2019-0236]\]                                                     To evaluate the AD effects of a single, repeated, and maintenance infusion of ketamine                                                 TRD                                                                                 Double-blind, randomized comparison of single infusions of IN ketamine and placebo                                                                                        IV                        41            MADRS                               Repeated ketamine infusions have cumulative and sustained antidepressant effects
  6 ketamine infusions thrice weekly over 2 weeks (after relapse of depressive symptoms)      Reductions in depressive symptoms were maintained among responders through once-weekly infusions                                                                                                                                                                                                                                                                                                                                                                                 
  Responders received four additional infusions once weekly (maintenance)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Daly et al. \[[@b85-pi-2019-0236]\]                                                         To assess the efficacy of delaying depressive symptoms relapse in TRD in stable remission                                              TRD patients in remission and stable TRD patients who have responded to treatment   Double-blind, randomized withdrawal study Continue IN esketamine vs. discontinue IN esketamine (converted to placebo) with oral antidepressant treatment in both groups   IN                        297           Time to relapse                     Ketamine+AD group had fewer relapses than the placebo+AD group in both stable remission and stable response
  Popova et al. \[[@b86-pi-2019-0236]\]                                                       To assess the efficacy of switching patients with TRD from an ineffective AD to flexibly dosed IN ketamine plus a newly initiated AD   TRD                                                                                 Double-blind, randomized, placebo-controlled trial                                                                                                                        IN                        197           MADRS                               Ketamine+newly initiated AD reduced more depressive symptoms than placebo+newly initiated AD
  IN flexible dose of ketamine (28 mg, 56 mg, or 84 mg) vs. placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Twice weekly, for up to 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

IV: intravenous, TRD: treatment-resistant depression, MADRS: Montgomery-Åsberg Depression Rating Scale, HAMD-6: the 6-item Hamilton Depression Rating Scale, IN: intranasal, MDD: major depressive disorder, AD: antidepressant
